ADCT
ADC Therapeutics SA
$
4.060
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.075
Open
4.000
VWAP
4.02
Vol
359.69K
Mkt Cap
501.70M
Low
3.900
Amount
1.45M
EV/EBITDA(TTM)
--
Total Shares
96.23M
EV
722.34M
EV/OCF(TTM)
--
P/S(TTM)
6.23
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
18.70M
-0.74%
-0.280
-44%
18.70M
-18.81%
-0.280
-22.22%
18.33M
+8.4%
-0.342
+17.93%
Estimates Revision
The market is revising Downward the revenue expectations for ADC Therapeutics SA (ADCT) for FY2025, with the revenue forecasts being adjusted by -1.67% over the past three months. During the same period, the stock price has changed by 31.39%.
Revenue Estimates for FY2025
Revise Downward
-1.67%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.65%
In Past 3 Month
Stock Price
Go Up
+31.39%
In Past 3 Month
3 Analyst Rating
Wall Street analysts forecast ADCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADCT is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.060
Low
5.00
Averages
7.33
High
10.00
Current: 4.060
Low
5.00
Averages
7.33
High
10.00
H.C. Wainwright
Robert Burns
Buy
downgrade
$8 -> $7
2025-10-16
Reason
H.C. Wainwright
Robert Burns
Price Target
$8 -> $7
2025-10-16
downgrade
Buy
Reason
H.C. Wainwright analyst Robert Burns lowered the firm's price target on ADC Therapeutics to $7 from $8 and keeps a Buy rating on the shares. The firm reduced the price target after factoring in the private placement financing.
RBC Capital
Gregory Renza
Outperform
downgrade
$8 -> $5
2025-06-21
Reason
RBC Capital
Gregory Renza
Price Target
$8 -> $5
2025-06-21
downgrade
Outperform
Reason
RBC Capital analyst Gregory Renza lowered the firm's price target on ADC Therapeutics to $5 from $8 but keeps an Outperform rating on the shares. The firm says the company's high efficacy for Zynlonta in DLBCL gives it confidence in its likelihood to show clinically meaningful benefits in the 2nd line LOTIS-5 study, unlocking an additional $200M+ U.S. sales opportunity, the analyst tells investors in a research note. RBC adds that ADC shares are undervalued on the balance of a largely de-risked asset with multiple expansion opportunities that can reaccelerate growth.
Guggenheim
Buy
maintain
$7 -> $10
2025-06-13
Reason
Guggenheim
Price Target
$7 -> $10
2025-06-13
maintain
Buy
Reason
Guggenheim raised the firm's price target on ADC Therapeutics to $10 from $7 and keeps a Buy rating on the shares after the company released an update on their Phase 1b LOTIS-7 study of Zynlonta plus glofitamab as part of the EHA embargo lift. ADC also announced a $100M private placement financing intended to support Zynlonta's ongoing clinical programs and commercialization in earlier line DLBCL, as well as a restructuring comprising a 30% reduction in force and closure of UK operations, notes the analyst, who is updating the firm's estimates for all of these events.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$8
2025-03-31
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$8
2025-03-31
Reiterates
Strong Buy
Reason
Guggenheim
Michael Schmidt
Strong Buy
Maintains
$10 → $7
2025-03-31
Reason
Guggenheim
Michael Schmidt
Price Target
$10 → $7
2025-03-31
Maintains
Strong Buy
Reason
Guggenheim lowered the firm's price target on ADC Therapeutics to $7 from $10 and keeps a Buy rating on the shares. Q4 results were largely consistent with prior disclosures, though Zynlonta sales of $16.4M came in below Street consensus, the analyst tells investors. The firm is updating its model to reflect a slightly more conservative timeline for potential Zynlonta label expansion into second-line Diffuse Large B-Cell Lymphoma as well as Q4 financial results.
Cantor Fitzgerald
Eric Schmidt
Buy
Reiterates
n/a
2025-03-07
Reason
Cantor Fitzgerald
Eric Schmidt
Price Target
n/a
2025-03-07
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for ADC Therapeutics SA (ADCT.N) is -3.76, compared to its 5-year average forward P/E of -3.54. For a more detailed relative valuation and DCF analysis to assess ADC Therapeutics SA 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.54
Current PE
-3.76
Overvalued PE
-0.37
Undervalued PE
-6.71
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.63
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.48
Undervalued EV/EBITDA
-6.79
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
18.07
Current PS
4.05
Overvalued PS
61.89
Undervalued PS
-25.74
Financials
Annual
Quarterly
FY2025Q3
YoY :
-11.03%
16.43M
Total Revenue
FY2025Q3
YoY :
-13.98%
-30.59M
Operating Profit
FY2025Q3
YoY :
-6.28%
-40.97M
Net Income after Tax
FY2025Q3
YoY :
-28.57%
-0.30
EPS - Diluted
FY2025Q3
YoY :
+18.61%
-29.96M
Free Cash Flow
FY2025Q3
YoY :
-2.84%
92.68
Gross Profit Margin - %
FY2025Q3
-176.29
FCF Margin - %
FY2025Q3
YoY :
+4.72%
-249.38
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
52.5K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
2
609.0K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
2.5K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
52.5K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
2
609.0K
USD
Months
ADCT News & Events
Events Timeline
2025-11-10 (ET)
2025-11-10
07:37:44
ADC Therapeutics announces Q3 adjusted EPS of 19 cents, falling short of consensus estimate of 36 cents.
2025-10-13 (ET)
2025-10-13
07:36:26
ADC Therapeutics reports approximately $15.8M in Q3 sales for Zynlonta
2025-10-13
07:34:32
ADC Therapeutics reveals $60 million private placement deal
Sign Up For More Events
Sign Up For More Events
News
9.5
11-10PRnewswireADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
9.5
11-07NASDAQ.COMMettler-Toledo Exceeds Q3 Earnings Expectations Despite Year-over-Year Sales Drop
1.0
11-03Yahoo FinanceADC Therapeutics to Hold Conference Call for Q3 2025 Financial Results on November 10, 2025
Sign Up For More News
People Also Watch
FAQ
What is ADC Therapeutics SA (ADCT) stock price today?
The current price of ADCT is 4.06 USD — it has increased 0.25 % in the last trading day.
What is ADC Therapeutics SA (ADCT)'s business?
What is the price predicton of ADCT Stock?
What is ADC Therapeutics SA (ADCT)'s revenue for the last quarter?
What is ADC Therapeutics SA (ADCT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for ADC Therapeutics SA (ADCT)'s fundamentals?
How many employees does ADC Therapeutics SA (ADCT). have?